MariMed Core Brand Sells Well In Massachusetts, According To BDSA

Amid the persistent headwinds facing the U.S. cannabis retail market right now, MariMed, Inc. (CNSX: MRMD) (OTCMKTS: MRMD) has positive sales data points to report. The company reports that according to BDSA data, Marimed’s Nature’s Heritage brand was second in market share for 1/8 flower volume share in Massachusetts, illustrating the power of its branding in The Bay State.

BDSA is one of the leading market analytics firm covering the legal cannabis markets in North America. BDSA tracks cannabis product sales, buying trends, industry segment by performance, and packages that data to consumers, businesses and research analysts.

Launched in Maryland in Q1 2018 and Massachusetts in February 2020, Nature’s Heritage has become one of MariMed’s flagship and best selling products. Over time, the company has expanded its line of products derived from its Nature’s Heritage premium flower brand to include solventless concentrates, a variety of RSO products, vaporizers, and pre-rolls.

Recently, MariMed announced the launch of Nature’s Heritage ‘LIVE Flower’, using a proprietary FreshCure curing process that flash-freezes Nature’s Heritage craft flower within hours of trimming, thus locking in the natural terpenes and cannabinoid profiles. The flower is further refined through barrel-cure guidelines specific to each flower strain to achieve optimal moisture levels, and sold in heavy, opaque packaging designed to prevent light and oxidation of the plant.

The launch of ‘LIVE Flower’ is an extension of product offering which attempt to cater to specific niche consumer segments to maximize overall sales. MariMed sports an assortment of brands which covers every type of personal and economic demographic possible. The company also partners with qualified operators to manufacture and distribute MariMed’s products, in an effort to expand consumer reach.

With MariMed placing a high premium branding and consumer segmentation to drive sales growth, expect more such innovative product announcements in the months ahead.


* In accordance with an executed agreement between The Dales Report and MariMed, The Dales Report is engaged with the aforementioned on a 12-month contract for $7,500 per month, with the purpose of publicly disseminating information pertaining to MariMed via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More